Clinical characteristics and autoantibody profile of the patients with polymyositis/dermatomyositis.
| Patient Characteristics | Frequency/mean |
|---|---|
| Diagnosis | |
| Polymyositis | 77% |
| Dermatomyositis | 23% |
| Sex | |
| Male | 10% |
| Female | 90% |
| Mean age at onset, yrs, ± SD | 42.3 ± 1.6 |
| Raynaud sign | 33.3% |
| Proximal muscle weakness | 87% |
| Neck muscle weakness | 3.3% |
| Distal muscle weakness | 3.3% |
| Myalgia/arthralgia | 10% |
| Weight loss | 3.3% |
| Dysphagia | 16.7% |
| Erythema | 16.7% |
| Lung disease | 36.7% |
| SBP, mmHg | 120 ± 2 |
| DBP, mmHg | 76.1 ± 1 |
| HR, beat/min | 85 ± 1 |
| Serum cholesterol, mmol/l | 4.65 ± 0.13 |
| Serum triglyceride, mmol/l | 1.41 ± 0.11 |
| Blood glucose, mmol/l | 5.08 ± 0.18 |
| Uric acid, μmol/l | 289.4 ± 12.51 |
| CK activity, U/l | 1065.23 ± 222.38 |
| Muscle histology | |
| Negative | 13.3% |
| Mononuclear infiltration | 80% |
| Chronic inflammation | 6.7% |
| Specific therapy | |
| Steroid | 100% |
| Cyclosporine | 13.3% |
| Anti-dsDNA | 0% |
| Anti-EJ (glycyl-tRNA synthetase) | 0% |
| Anti-Jo1 (histidyl-tRNA synthetase) | 20% |
| Anti-Ku (Ku antigen) | 0% |
| Anti-Mi-2B (nuclear helicase) | 0% |
| Anti-OJ (isoleucyl-tRNA synthetase) | 0% |
| Anti-PL-12 (alanyl-tRNA synthetase) | 0% |
| Anti-PL-7 (threonyl-tRNA synthetase) | 0% |
| Anti-PM/Scl-100 (PM/Scl-100 antigen) | 3.3% |
| Anti-PM/Scl-75 (PM/Scl-75 antigen) | 10% |
| Anti-Ro-52 (Ro-52 antigen) | 20% |
| Anti-Scl-70 (type I topoisomerase) | 43.3% |
| Anti-SRP (signal recognition particle) | 0% |
Autoantibodies’ targets are listed in parentheses. SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; CK: creatine kinase.